Staphylococcal Vaccines
Vaccines
Vaccines, Inactivated
Viral Vaccines
Vaccines, DNA
Vaccines, Synthetic
Broadly protective vaccine for Staphylococcus aureus based on an in vivo-expressed antigen. (1/79)
Vaccines based on preferential expression of bacterial antigens during human infection have not been described. Staphylococcus aureus synthesized poly-N-succinyl beta-1-6 glucosamine (PNSG) as a surface polysaccharide during human and animal infection, but few strains expressed PNSG in vitro. All S. aureus strains examined carried genes for PNSG synthesis. Immunization protected mice against kidney infections and death from strains that produced little PNSG in vitro. Nonimmune infected animals made antibody to PNSG, but serial in vitro cultures of kidney isolates yielded mostly cells that did not produce PNSG. PNSG is a candidate for use in a vaccine to protect against S. aureus infection. (+info)Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. (2/79)
BACKGROUND: In patients with decreased resistance to infection, Staphylococcus aureus is a major cause of bacteremia and its complications. The capsular polysaccharides are essential for the pathogenesis of and immunity to S. aureus infection and are targets for vaccines. METHODS: In a double-blind trial involving patients with end-stage renal disease who were receiving hemodialysis, we evaluated the safety, immunogenicity, and efficacy of a vaccine with S. aureus type 5 and 8 capsular polysaccharides conjugated to nontoxic recombinant Pseudomonas aeruginosa exotoxin A. Between April 1998 and August 1999, 1804 adult patients at 73 hemodialysis centers were randomly assigned to receive a single intramuscular injection of either vaccine or saline. IgG antibodies to S. aureus type 5 and 8 capsular polysaccharides were measured for up to two years, and episodes of S. aureus bacteremia were recorded. Efficacy was estimated by comparing the incidence of S. aureus bacteremia in the patients who received the vaccine with the incidence in the control patients. RESULTS: Reactions to the vaccine were generally mild to moderate, and most resolved within two days. The capsular polysaccharides elicited an antibody response of at least 80 microg per milliliter (the estimated minimal level conferring protection) in 80 percent of patients for type 5 and in 75 percent of patients for type 8. The efficacy during weeks 3 to 54 was only 26 percent (P=0.23). However, between weeks 3 and 40 after vaccination, S. aureus bacteremia developed in 11 of 892 patients in the vaccine group who could be evaluated for bacteremia, as compared with 26 of 906 patients in the control group (estimate of efficacy, 57 percent; 95 percent confidence interval, 10 to 81 percent; nominal P=0.02). CONCLUSIONS: In patients receiving hemodialysis, a conjugate vaccine can confer partial immunity against S. aureus bacteremia for approximately 40 weeks, after which protection wanes as antibody levels decrease. (+info)Structural basis for abrogated binding between staphylococcal enterotoxin A superantigen vaccine and MHC-IIalpha. (3/79)
Staphylococcal enterotoxins (SEs) are superantigenic protein toxins responsible for a number of life-threatening diseases. The X-ray structure of a staphylococcal enterotoxin A (SEA) triple-mutant (L48R, D70R, and Y92A) vaccine reveals a cascade of structural rearrangements located in three loop regions essential for binding the alpha subunit of major histocompatibility complex class II (MHC-II) molecules. A comparison of hypothetical model complexes between SEA and the SEA triple mutant with MHC-II HLA-DR1 clearly shows disruption of key ionic and hydrophobic interactions necessary for forming the complex. Extensive dislocation of the disulfide loop in particular interferes with MHC-IIalpha binding. The triple-mutant structure provides new insights into the loss of superantigenicity and toxicity of an engineered superantigen and provides a basis for further design of enterotoxin vaccines. (+info)Immune protection against staphylococcal enterotoxin-induced toxic shock by vaccination with a Venezuelan equine encephalitis virus replicon. (4/79)
A candidate vaccine against staphylococcal enterotoxin B (SEB) was developed using a Venezuelan equine encephalitis (VEE) virus vector. This vaccine is composed of a self-replicating RNA, termed "replicon," containing the VEE nonstructural genes and cis-acting elements and a gene encoding mutagenized SEB (mSEB). Cotransfection of baby hamster kidney cells with the mSEB replicon and 2 helper RNA molecules resulted in the release of propagation-deficient mSEB-VEE replicon particles (mSEB-VRPs). Mice inoculated subcutaneously with mSEB-VRPs were protected (15 of 20 mice) from a challenge with 5 median lethal dose units of wild-type (wt) SEB. T cells from mice vaccinated with mSEB-VRP responded normally both in vitro to wt SEB and in recall response to the inactivated mSEB polypeptide. The profile of cytokines measured after challenge with wt SEB suggested that the mode of protection was predominantly Th1 dependent. Our results suggest that the VEE replicon is a practical and convenient model system for evaluating efficacy of vaccines for the control of bacterial diseases. (+info)Identification of in vivo expressed vaccine candidate antigens from Staphylococcus aureus. (5/79)
For the design of potent subunit vaccines, it is of paramount importance to identify all antigens immunologically recognized by a patient population infected with a pathogen. We have developed a rapid and efficient procedure to identify such commonly recognized antigens, and here we provide a comprehensive in vivo antigenic profile of Staphylococcus aureus, an important human pathogen. S. aureus peptides were displayed on the surface of Escherichia coli via fusion to one of two outer membrane proteins (LamB and FhuA) and probed with sera selected for high Ab titer and opsonic activity. A total of 60 antigenic proteins were identified, most of which are located or predicted to be located on the surface of the bacterium or secreted. The identification of these antigens and their reactivity with individual sera from patients and healthy individuals greatly facilitate the selection of promising vaccine candidates for further evaluation. This approach, which makes use of whole genome sequence information, has the potential to greatly accelerate and facilitate the formulation of novel vaccines and is applicable to any pathogen that induces Abs in humans and/or experimental animals. (+info)Functional selection of vaccine candidate peptides from Staphylococcus aureus whole-genome expression libraries in vitro. (6/79)
An in vitro protein selection method, ribosome display, has been applied to comprehensively identify and map the immunologically relevant proteins of the human pathogen Staphylococcus aureus. A library built up from genomic fragments of the virulent S. aureus COL strain (methicillin-resistant S. aureus) allowed us to screen all possible encoded peptides for immunoreactivity. As selective agents, human sera exhibiting a high antibody titer and opsonic activity against S. aureus were used, since these antibodies indicate the in vivo expression and immunoreactivity of the corresponding proteins. Identified clones cluster in distinct regions of 75 genes, most of them classifiable as secreted or surface-localized proteins, including previously identified virulence factors. In addition, 14 putative novel short open reading frames were identified and their immunoreactivity and in vivo mRNA expression were confirmed, underscoring the annotation-independent, true genomic nature of our approach. Evidence is provided that a large fraction of the identified peptides cannot be expressed in an in vivo-based surface display system. Thus, in vitro protein selection, not biased by the context of living entities, allows screening of genomic expression libraries with a large number of different ligands simultaneously. It is a powerful approach for fingerprinting the repertoire of immune reactive proteins serving as target candidates for active and passive vaccination against pathogens. (+info)RUNT DISEASE INDUCED IN NEONATAL MICE BY STERILE BACTERIAL VACCINES. (7/79)
A form of runt disease has been produced in neonatal CF-1 and ICR mice by the repeated injection of 10(9) washed, autoclaved, saline-suspended staphylococci or streptococci. The most severely affected animals showed a marked decrease in lymphoid tissues and resembled grossly and microscopically animals suffering from the classical runt or wasting disease described by others. The timing of the initial antigenic stimulation was of importance, and animals started on their course of injections at an age of 48 hours or older showed no effect. There was a considerable variation in the severity of the disease within litters and from one litter to another. This variation could not be ascribed to a difference in susceptibility between sexes, since both male and female mice were observed to runt under appropriate conditions. Germ-free ICR mice were much more resistant to the runting phenomenon than conventional animals of the same strain, but could be induced to runt by injection of the staphylococcal vaccine suspended in homologous antiserum. The relationship of the runting phenomenon described here and classical runt disease or runting by adrenal hormones is discussed. (+info)Comparative opsonic and protective activities of Staphylococcus aureus conjugate vaccines containing native or deacetylated Staphylococcal Poly-N-acetyl-beta-(1-6)-glucosamine. (8/79)
Staphylococcus aureus and Staphylococcus epidermidis both synthesize the surface polysaccharide poly-N-acetyl-beta-(1-6)-glucosamine (PNAG), which is produced in vitro with a high level (>90%) of the amino groups substituted by acetate. Here, we examined the role of the acetate substituents of PNAG in generating opsonic and protective antibodies. PNAG and a deacetylated form of the antigen (dPNAG; 15% acetylation) were conjugated to the carrier protein diphtheria toxoid (DT) and used to immunize animals. Mice responded in a dose-dependent fashion to both conjugate vaccines, with maximum antibody titers observed at the highest dose and 4 weeks after the last of three weekly immunizations. PNAG-DT and dPNAG-DT vaccines were also very immunogenic in rabbits. Antibodies raised to the conjugate vaccines in rabbits mediated the opsonic killing of various staphylococcal strains, but the specificity of the opsonic killing was primarily to dPNAG, as this antigen inhibited the killing of S. aureus strains by both PNAG- and dPNAG-specific antibodies. Passive immunization of mice with anti-dPNAG-DT rabbit sera showed significant levels of clearance of S. aureus from the blood (54 to 91%) compared to control mice immunized with normal rabbit sera, whereas PNAG-specific antibodies were ineffective at clearing S. aureus. Passive immunization of mice with a goat antiserum raised to the dPNAG-DT vaccine protected against a lethal dose of three different S. aureus strains. Overall, these data show that immunization of animals with a conjugate vaccine of dPNAG elicit antibodies that mediated opsonic killing and protected against S. aureus infection, including capsular polysaccharide types 5 and 8 and an untypable strain. (+info)Staphylococcal vaccines are immunizations that are developed to protect against infections caused by the Staphylococcus bacteria, particularly Staphylococcus aureus. These vaccines typically contain components of the bacterial cell wall or toxins that stimulate an immune response in the body, leading to the production of antibodies that can recognize and neutralize the bacteria if they invade the body in the future.
There are currently no licensed staphylococcal vaccines available for use in humans, although several candidates are in various stages of development. These vaccines aim to prevent a range of staphylococcal infections, including skin and soft tissue infections, pneumonia, bloodstream infections, and toxic shock syndrome.
It's important to note that while antibiotics can be effective against staphylococcal infections, the bacteria have become increasingly resistant to these drugs over time, making vaccines an important area of research and development for preventing and controlling the spread of these infections.
A vaccine is a biological preparation that provides active acquired immunity to a particular infectious disease. It typically contains an agent that resembles the disease-causing microorganism and is often made from weakened or killed forms of the microbe, its toxins, or one of its surface proteins. The agent stimulates the body's immune system to recognize the agent as a threat, destroy it, and "remember" it, so that the immune system can more easily recognize and destroy any of these microorganisms that it encounters in the future.
Vaccines can be prophylactic (to prevent or ameliorate the effects of a future infection by a natural or "wild" pathogen), or therapeutic (to fight disease that is already present). The administration of vaccines is called vaccination. Vaccinations are generally administered through needle injections, but can also be administered by mouth or sprayed into the nose.
The term "vaccine" comes from Edward Jenner's 1796 use of cowpox to create immunity to smallpox. The first successful vaccine was developed in 1796 by Edward Jenner, who showed that milkmaids who had contracted cowpox did not get smallpox. He reasoned that exposure to cowpox protected against smallpox and tested his theory by injecting a boy with pus from a cowpox sore and then exposing him to smallpox, which the boy did not contract. The word "vaccine" is derived from Variolae vaccinae (smallpox of the cow), the term devised by Jenner to denote cowpox. He used it in 1798 during a conversation with a fellow physician and later in the title of his 1801 Inquiry.
Inactivated vaccines, also known as killed or non-live vaccines, are created by using a version of the virus or bacteria that has been grown in a laboratory and then killed or inactivated with chemicals, heat, or radiation. This process renders the organism unable to cause disease, but still capable of stimulating an immune response when introduced into the body.
Inactivated vaccines are generally considered safer than live attenuated vaccines since they cannot revert back to a virulent form and cause illness. However, they may require multiple doses or booster shots to maintain immunity because the immune response generated by inactivated vaccines is not as robust as that produced by live vaccines. Examples of inactivated vaccines include those for hepatitis A, rabies, and influenza (inactivated flu vaccine).
A viral vaccine is a biological preparation that introduces your body to a specific virus in a way that helps your immune system build up protection against the virus without causing the illness. Viral vaccines can be made from weakened or inactivated forms of the virus, or parts of the virus such as proteins or sugars. Once introduced to the body, the immune system recognizes the virus as foreign and produces an immune response, including the production of antibodies. These antibodies remain in the body and provide immunity against future infection with that specific virus.
Viral vaccines are important tools for preventing infectious diseases caused by viruses, such as influenza, measles, mumps, rubella, polio, hepatitis A and B, rabies, rotavirus, chickenpox, shingles, and some types of cancer. Vaccination programs have led to the control or elimination of many infectious diseases that were once common.
It's important to note that viral vaccines are not effective against bacterial infections, and separate vaccines must be developed for each type of virus. Additionally, because viruses can mutate over time, it is necessary to update some viral vaccines periodically to ensure continued protection.
Combined vaccines are defined in medical terms as vaccines that contain two or more antigens from different diseases, which are given to provide protection against multiple diseases at the same time. This approach reduces the number of injections required and simplifies the immunization schedule, especially during early childhood. Examples of combined vaccines include:
1. DTaP-Hib-IPV (e.g., Pentacel): A vaccine that combines diphtheria, tetanus, pertussis (whooping cough), Haemophilus influenzae type b (Hib) disease, and poliovirus components in one injection to protect against these five diseases.
2. MMRV (e.g., ProQuad): A vaccine that combines measles, mumps, rubella, and varicella (chickenpox) antigens in a single injection to provide immunity against all four diseases.
3. HepA-HepB (e.g., Twinrix): A vaccine that combines hepatitis A and hepatitis B antigens in one injection, providing protection against both types of hepatitis.
4. MenACWY-TT (e.g., MenQuadfi): A vaccine that combines four serogroups of meningococcal bacteria (A, C, W, Y) with tetanus toxoid as a carrier protein in one injection for the prevention of invasive meningococcal disease caused by these serogroups.
5. PCV13-PPSV23 (e.g., Vaxneuvance): A vaccine that combines 13 pneumococcal serotypes with PPSV23, providing protection against a broader range of pneumococcal diseases in adults aged 18 years and older.
Combined vaccines have been thoroughly tested for safety and efficacy to ensure they provide a strong immune response and an acceptable safety profile. They are essential tools in preventing various infectious diseases and improving overall public health.
I could not find a specific medical definition for "Vaccines, DNA." However, I can provide you with some information about DNA vaccines.
DNA vaccines are a type of vaccine that uses genetically engineered DNA to stimulate an immune response in the body. They work by introducing a small piece of DNA into the body that contains the genetic code for a specific antigen (a substance that triggers an immune response). The cells of the body then use this DNA to produce the antigen, which prompts the immune system to recognize and attack it.
DNA vaccines have several advantages over traditional vaccines. They are relatively easy to produce, can be stored at room temperature, and can be designed to protect against a wide range of diseases. Additionally, because they use DNA to stimulate an immune response, DNA vaccines do not require the growth and culture of viruses or bacteria, which can make them safer than traditional vaccines.
DNA vaccines are still in the experimental stages, and more research is needed to determine their safety and effectiveness. However, they have shown promise in animal studies and are being investigated as a potential tool for preventing a variety of infectious diseases, including influenza, HIV, and cancer.
Synthetic vaccines are artificially produced, designed to stimulate an immune response and provide protection against specific diseases. Unlike traditional vaccines that are derived from weakened or killed pathogens, synthetic vaccines are created using synthetic components, such as synthesized viral proteins, DNA, or RNA. These components mimic the disease-causing agent and trigger an immune response without causing the actual disease. The use of synthetic vaccines offers advantages in terms of safety, consistency, and scalability in production, making them valuable tools for preventing infectious diseases.
Bacterial vaccines are types of vaccines that are created using bacteria or parts of bacteria as the immunogen, which is the substance that triggers an immune response in the body. The purpose of a bacterial vaccine is to stimulate the immune system to develop protection against specific bacterial infections.
There are several types of bacterial vaccines, including:
1. Inactivated or killed whole-cell vaccines: These vaccines contain entire bacteria that have been killed or inactivated through various methods, such as heat or chemicals. The bacteria can no longer cause disease, but they still retain the ability to stimulate an immune response.
2. Subunit, protein, or polysaccharide vaccines: These vaccines use specific components of the bacterium, such as proteins or polysaccharides, that are known to trigger an immune response. By using only these components, the vaccine can avoid using the entire bacterium, which may reduce the risk of adverse reactions.
3. Live attenuated vaccines: These vaccines contain live bacteria that have been weakened or attenuated so that they cannot cause disease but still retain the ability to stimulate an immune response. This type of vaccine can provide long-lasting immunity, but it may not be suitable for people with weakened immune systems.
Bacterial vaccines are essential tools in preventing and controlling bacterial infections, reducing the burden of diseases such as tuberculosis, pneumococcal disease, meningococcal disease, and Haemophilus influenzae type b (Hib) disease. They work by exposing the immune system to a harmless form of the bacteria or its components, which triggers the production of antibodies and memory cells that can recognize and fight off future infections with that same bacterium.
It's important to note that while vaccines are generally safe and effective, they may cause mild side effects such as pain, redness, or swelling at the injection site, fever, or fatigue. Serious side effects are rare but can occur, so it's essential to consult with a healthcare provider before receiving any vaccine.
Chronic fatigue syndrome treatment
Autogenous vaccines
Charles Nicolle
Trudy Virginia Noller Murphy
Institut Pasteur de Dalat
Staphylococcus aureus
List of MeSH codes (D20)
Tetramer assay
Pox party
Kawasaki disease
Macfarlane Burnet
Staphylococcus aureus alpha toxin
Vincent Fischetti
PPIB
Scarlet fever
Staphylococcus hominis
Poultry disease
Harrison's Principles of Internal Medicine
Toll-like receptor 2
Madarosis
Alan W. Bernheimer
United States biological defense program
Biological warfare
Dedicator of cytokinesis protein 8
Blood irradiation therapy
Gastroenteritis
Sharon Peacock
Skin infection
Chemical Corps
Staphylococcus hyicus
Third-Generation Smallpox Vaccines in the Absence of Clinical Smallpox
Heterotaxy Syndrome and Primary Ciliary Dyskinesia Medication: Diuretic agents, Inotropic agents, Angiotensin-converting enzyme...
Advanced Search Results - Public Health Image Library(PHIL)
RFA-AI-14-016: NIAID Division of Allergy, Immunology and Transplantation: Statistical and Clinical Coordinating Center (UM2)
Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis - PubMed
Laboratory Contributions to Public Health
Infections: MedlinePlus
S aureus Vaccine for Heart Surgery Appears Harmful
Staphylococcal Meningitis: Background, Pathophysiology, Etiology
Chronic fatigue syndrome treatment - Wikipedia
Poliomyelitis in Idaho after use of live virus vaccine
Cholera Medication: Antibiotics, Vaccines
In vitro affinity maturation of a specificity-determining region-grafted humanized anticarcinoma antibody: isolation and...
MeSH Browser
MeSH Browser
In silico construction of a multiepitope Zika virus vaccine using immunoinformatics tools | Scientific Reports
Collaborations : USDA ARS
How I Treat Methicillin-Resistant Staphylococcal Pyoderma - WSAVA 2014 Congress - VIN
MIS-C After COVID Vaccination Exceedingly Rare in Young People | MedPage Today
Enhanced Oral Delivery of Biopharmaceuticals - the University of Bath's research portal
NIH VideoCast - Ricin as a Bioterror Weapon: Pathogenesis and Potential Countermeasures
C64329|Hemiplegia|create|26-JAN-07|(null)|(null
Impact of early life exposures to geohelminth infections on the development of vaccine immunity, allergic sensitization, and...
When to Keep Your Child Home From Child Care - HealthyChildren.org
Infections9
- These are increasingly severe staphylococcal skin infections. (medscape.com)
- 2 It commonly follows superficial Staphylococcal infections of the umbilical, pectoral and perineal areas and may follow procedures like circumcision. (ispub.com)
- Based on 40+ years of research, ImmLab has developed novel technological inventions for the prevention and treatment of staphylococcal infections in humans and animals. (immlab.com)
- ImmLab's product line of staphylococcal-lysate-based vaccines for prevention and treatment of staphylococcal infections in humans, companion animals, and farm animals not only improves the health and well-being of those subject to microbial infections but does so using an approach that will not add to the growing threat of antibiotic-resistant bacterial strains and super-pathogens. (immlab.com)
- Vaccines are available as aids to prevent abortion due to EHV-1 infections. (ontario.ca)
- Prosthetic Knee Infection by a-hemolytic Streptococcus Species Prosthetic joint infections are most commonly caused by staphylococcal species, but this case of a prosthetic knee infection demonstrates the potential of a-hemolytic Streptococcus infection as well. (medscape.com)
- Should First-line Empiric Treatment Strategies for Neonates Cover Coagulase-negative Staphylococcal Infections in Kenya? (kemri-wellcome.org)
- We are excited about the potential impact this vaccine could have in preventing S. aureus infections, which have long posed significant challenges to global health and where antibiotic resistance is developing fast," said Birgitte Rønø, Chief Scientific Officer at Evaxion. (evaxion-biotech.com)
- If the mice had staph infections prior to vaccination, we believe the vaccine candidates may not work. (scienceinter.com)
Staphylococcus5
- A vaccine to prevent postoperative infection with Staphylococcus aureus in patients undergoing cardiothoracic surgery is associated with an overall lack of efficacy and a higher mortality rate among patients who become infected, according to a study published in the April 3 issue of JAMA . (medscape.com)
- Our aim was to provide information about the production of Egg White Immunoglobulin (EWIg) with specificity to Staphylococcal protein-A , a surface antigen of Staphylococcus aureus and to study the inhibition of this bacterium growth in pre- and post-immunized hens. (omicsonline.org)
- In the ongoing search for a vaccine to battle the aggressive methicillin-resistant staphylococcus aureus, a University of Southern Mississippi biological science professor and student have developed an online database that holds collected data on genes related to staph. (technologynetworks.com)
- The poster entitled "EVX-B1: An AI-designed vaccine against Staphylococcus aureus , demonstrating full disease protection and complete bacterial clearance" is presented at the Staphylococcal Diseases Gordon Research Conference in New Hampshire, USA, taking place from 30th of July to 4 t h of August this year ( https://www.grc.org/staphylococcal-diseases-conference/2023/ ). (evaxion-biotech.com)
- Researchers believe they have discovered why multiple human clinical trials of staphylococcus vaccines have failed: the bacteria knows too much about us. (scienceinter.com)
Enterotoxin2
- You may not die immediately, but you will die because they have weaponized synthetically recreated crate venom, cobra venom, HIV glycoprotein 120, and what's called staphylococcal Enterotoxin D, which is a very aggressive gram-positive bacteria," she warned. (naturalnews.com)
- Establishment of a new animal model of allergic rhinitis with biphasic sneezing by intranasal sensitization with Staphylococcal enterotoxin B. Exp Ther Med. (southernbiotech.com)
Bacterial7
- Staphylococcal TSS is a potentially life-threatening systemic bacterial intoxication. (medscape.com)
- Primary direct effect: vaccines against bacterial diseases reduce the incidence of the disease and consequently the use of antibiotics. (unime.it)
- The IsdB vaccine worked in mice that had never been exposed to normal staph, generating antibodies that targeted the entire protein and disrupted bacterial functions. (scienceinter.com)
- However, in mice that had previously been exposed to staph, the vaccine only produced antibodies against the unprotected portion of the IsdB protein, leaving bacterial function unaffected. (scienceinter.com)
- This retrospective analysis of reported cases of meningitis in Bahrain aimed to assess the trend in the incidence of bacterial meningitis from 1990 to 2013, before and after the introduction of new vaccines. (who.int)
- The changing trend in the etiology of bacterial meningitis points to the need to study vaccination programme modifications, such as pneumococcal vaccine for the adult population, especially high-risk groups. (who.int)
- However, the epidemiol- the introduction of new vaccines and concerned with treatment of such cases ogy of bacterial meningitis continues the change in the incidence of bacterial in the country. (who.int)
Antibodies4
- The vaccine elicited antibodies but was not significantly more effective in preventing infection than placebo (22/3528 for recipients included in the analysis vs 27/3517 for control patients) at any time during the trial. (medscape.com)
- The vaccine elicitation of HIV-neutralizing antibodies with tier-2-neutralization breadth has been a challenge. (bvsalud.org)
- In addition, our group has also used our panel of well characterized monoclonal antibodies against S. mutans P1, a recognized target of protective immunity and widely studied candidate vaccine antigen, to demonstrate that exogenously administered antibodies included as part of an immune complex prior to immunization can be used in a directed and practical manner to alter the host antibody response against the bacteria towards one of increased efficacy. (ufl.edu)
- When researchers mixed human IsdB antibodies with vaccine-derived protective antibodies, the latter stopped working. (scienceinter.com)
20231
- COPENHAGEN, Denmark, July 31, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a clinical-stage biotechnology company specializing in the discovery and development of AI-powered immunotherapies, presents promising results of EVX-B1 at the Staphylococcal Diseases Gordon Research Conference in New Hampshire, USA. (evaxion-biotech.com)
COVID-19 Vaccine4
- 7-Year-Old Girl Oozes Blood from Eye After Receiving Pfizer COVID-19 Vaccine in Thailand. (healthimpactnews.com)
- A case study was published earlier this month in the Journal Français d'Ophtalmologie reporting an anterior uveitis case that developed after the first dose of COVID-19 vaccine in a 54-year-old female. (healthimpactnews.com)
- That's an average of 992 cases of eye disorders reported each month following COVID-19 vaccine injections, and this is most certainly NOT an exhaustive list of eye disorders. (healthimpactnews.com)
- Safety Monitoring of Novavax COVID-19 Vaccine in Those >12 Years This CDC report confirms the safety of the Novavax COVID-19 vaccine in adolescents and adults 12 years of age and older. (medscape.com)
Infection5
- Among all cases of S aureus infection, the 5 deaths attributed to multiorgan failure were all in vaccine recipients. (medscape.com)
- The researchers cite other vaccines that seemed to have made matters worse (influenza, respiratory syncytial virus, and dengue) and hypothesize that humoral immunity may be insufficient to prevent S aureus infection postoperatively. (medscape.com)
- Varicella vaccine seems to be effective in modifying the symptoms of varicella, but not potent enough in protecting from VZV infection. (vaccineriskawareness.com)
- The primary niche for S. aureus in humans is the nares, and nasal carriage is a documented risk factor for staphylococcal infection. (unipv.it)
- The mouse immunization studies demonstrate that ClfB is an attractive component for inclusion in a vaccine to reduce S. aureus nasal colonization in humans, which in turn may diminish the risk of staphylococcal infection. (unipv.it)
Strains6
- The search and study of genes related to staph is more imperative than ever to find a vaccine that can impact the new strains of staph. (technologynetworks.com)
- The coagglutination test, which uses staphylococcal protein A, for serotyping strains of Streptococcus pneumoniae, was extended to include serotyping within serogroups. (bmj.com)
- Fifty one strains of S pneumoniae, which belonged to one of the seven serogroups included in the 14 valent vaccine formulation, were tested, and no inconsistency was found when compared with the capsule swelling reaction. (bmj.com)
- The characteristics of poliovirus strains circulating in Ukraine in 1982-1994″ (Mikrobiol[ogie] Z. vol. 60, no. 2, March-April 1998, pp. 44-49 [article in Russian]): "The long-term use of the live poliomyelitis vaccine has not stopped circulation of virulent polioviruses. (vaccineriskawareness.com)
- However, these effects may be limited by the presence of microbial strains not included in vaccines or by their gene variation. (unime.it)
- The AI technology has enabled the identification of novel S. aureus antigens, paving the way for the development of a vaccine with potential for broad protection against clinically relevant strains. (evaxion-biotech.com)
Rotavirus Vaccines1
- In the United States before rotavirus vaccines became available, a wave of rotavirus illness would begin in the Southwest in December and end in the Northeast in April or May. (msdmanuals.com)
MRNA4
- A 54-year-old female patient, who did not have any disease other than diabetes mellitus, had complaints of redness, blurred vision, eye and headache that started in both eyes 3 days after the first dose of BNT162b2 mRNA (Pfizer-BioNTech) vaccine. (healthimpactnews.com)
- We have previously reported on a case of a 7-year-old girl in Thailand who began oozing blood from her eyes and skin after receiving the Pfizer mRNA vaccine. (healthimpactnews.com)
- According to the Multidisciplinary Digital Publishing Institute MDPI , there have been recent reports of hemorrhage, blood clots, and thrombocytopenia following the administration of mRNA COVID-19 vaccines that have raised concerns over the safety of genetic vaccines for people with pre-existing coagulation disorders or those on certain medications. (healthimpactnews.com)
- With the dangerous COVID-19 mRNA shots now being extended to babies and toddlers, I decided to search the Government VAERS ( Vaccine Adverse Reporting System ) database for cases filed for various eye disorders. (healthimpactnews.com)
Antigens3
- Studies on capsular serotyping of isolates are important for the rational design of mastitis vaccines, containing staphylococcal capsular antigens. (lupinepublishers.com)
- Our proprietary EDEN platform rapidly identifies novel, highly protective antigens for the use in pathogen-specific prophylactic vaccines against bacteria. (evaxion-biotech.com)
- Dennis undertook pioneering research on expression of virulence factors in the mammary gland during staphylococcal mastitis in sheep and cattle, and developed a vaccine adjuvant to target host defence mechanisms against these antigens leading to the patenting of a vaccine to control staphylococcal mastitis. (csiropedia.csiro.au)
Humans4
- Karen Kingston, a former Pfizer employee and current analyst who confirmed that the ingredients in the Wuhan coronavirus (COVID-19) vaccines are poison, revealed Pfizer-BioNTech's mission statement to strengthen the immune system to attack humans . (naturalnews.com)
- Exemption breeds familiarity: Why don't staph vaccines work in humans? (scienceinter.com)
- Staph vaccines appear to be so simple to make in laboratory mice because they rarely see S. aureus, but humans are exposed to staph beginning in the first weeks of life, and staph appears to have developed many strategies to render our immune response against them ineffective," Tsai explained. (scienceinter.com)
- To test their hypothesis, Liu, Tsai, and co-authors replicated one of the largest failed staph vaccine trials in humans by targeting the IsdB protein, which S. aureus uses to acquire needed iron for functioning. (scienceinter.com)
Immunization2
- The promising results showed the TSST-1 vaccine is safe and effective, with immunization lasting for at least two years. (noticiadesalud.com)
- At the age of 18 days, the rabbits were subcutaneously injected with 1 milliliter of the Bordetella vaccine, followed by a week of booster immunization and 2 milliliters subcutaneously. (inxfhmh.cn)
Viral Vaccines1
- Consider additional factors that will affect TB screening tests - TST and IGRA should not be completed within 4 weeks of live viral vaccines (which may have been given pre-departure - see below). (rch.org.au)
Mastitis2
- If improved vaccines against bovine mastitis are to be generated, more studies are required to elucidate the role of these polysaccharides in the pathogenesis of bovine mastitis [7]. (lupinepublishers.com)
- This data would help in formulating vaccine based strategies for control of mastitis. (lupinepublishers.com)
Bacteria4
- Other bacteria frequently identified from aborted feti include Leptospira, Nocardia, Klebsiella and Staphylococcal species. (ontario.ca)
- Vaccines contain either noninfectious components of bacteria or viruses or whole forms of these organisms that have been weakened. (msdmanuals.com)
- Reduction of antibiotic resistance of vaccine target bacteria. (unime.it)
- With the many previous unsuccessful attempts to develop an effective S. aureus vaccine, EVX-B1 instills renewed hope in the battle against the bacteria," said Steven Projan, PhD, Scientific Advisor to Evaxion and poster presenter. (evaxion-biotech.com)
MRSA2
- As researchers work to find a vaccine for MRSA, Elasri said this program can cut a significant amount of time it takes to find information about staphylococcal genes. (technologynetworks.com)
- Prevention, early recognition, and treatment of MRSA and TSS are crucial to prevent severe complications and improve outcomes," said Dr. Andreas Roetzer, Head of R&D for vaccines at Biomedical Research & Bio-Products AG. (noticiadesalud.com)
Pneumococcal1
- Examples of such vaccine interventions currently licensed include Hib and Pneumococcal conjugate vaccines while future vaccines under development in this category include Group B Streptococcal and Staphylococcal vaccines. (unime.it)
Antimicrobial1
- As targets for vaccine development and antimicrobial intervention are assessed, rodent nasal colonization models may be invaluable. (unipv.it)
Recombinant2
- We enrolled US Army Infantry trainees (Fort Benning, GA) in a phase 2, randomized, double-blind, placebo-controlled trial of NDV-3A, a vaccine containing a recombinant adhesin/invasion protein of Candida albicans that has structural similarity to the S. aureus protein clumping factor A. Study participants received one intramuscular dose of NDV-3A or placebo (adjuvant alone) within 72 h of arrival on base. (nih.gov)
- Likewise, mice that were immunized systemically or intranasally with a recombinant vaccine composed of domain A of ClfB exhibited lower levels of colonization than control animals exhibited. (unipv.it)
Prevention1
- Disease prevention strategies are needed, but a S. aureus vaccine does not currently exist. (nih.gov)
Candidates4
- The categories of species pangenome such as core, accessory, and unique genes sets can be analyzed for the identification of vaccine candidates through reverse vaccinology. (biomedcentral.com)
- The proposed pipeline has proved to be the first comprehensive automated pipeline that can precisely identify putative vaccine candidates exploiting the microbial pangenome. (biomedcentral.com)
- A significant decrease in time and cost is observed using this strategy instead of culturing the whole microorganism to identify potential vaccine candidates (PVCs) [ 9 ]. (biomedcentral.com)
- However, in all subsequent human trials, these vaccine candidates failed. (scienceinter.com)
Diseases4
- Diseases are disappearing as a result of vaccines. (vaccineriskawareness.com)
- 2. Secondary direct effect: vaccines can limit the use of antibiotics for secondary diseases by reducing the incidence of the primary disease. (unime.it)
- The use of vaccines is essential not only in children and the elderly, but also in subjects with particular morbid conditions such as cardiovascular, respiratory, metabolic diseases, primary and / or secondary immunosuppression, etc., which expose them to an increased risk of contracting invasive infectious diseases and developing serious complications in this case. (unime.it)
- It's a longstanding and enigma in the staphylococcal field," said George Liu, MD, PhD, professor of pediatrics at the University of California San Diego School of Medicine and chief of the Division of Infectious Diseases at Rady Children's Hospital-San Diego. (scienceinter.com)
Protective1
- Amid the novel coronavirus pandemic and beyond, the ImmLab human vaccine can be used in a protective anti-staphylococcal manner while also delivering significant benefits of specific and non-specific immunity boost needed for vulnerable populations. (immlab.com)
19981
- The incidence of meningitis due to H. influenzae and N. meningitidis showed a marked reduction after the introduction of the corresponding vaccines in 1998 and 2001 respectively, and S. pneumoniae became the predominant organism after Mycobacterium tuberculosis . (who.int)
Protein2
- Kingston further revealed that people are being injected with different versions of the vaccines: Some have weaponized spike protein in it, and some don't. (naturalnews.com)
- Here, we report the isolation and characteristics of a CD4-binding site specific monoclonal antibody, HmAb64, from a human volunteer immunized with a polyvalent gp120 DNA prime-protein boost vaccine. (bvsalud.org)
Proteins1
- ImmLab staphylococcal vaccines are created by introducing the genome of the staphylococcal bacteriophage into the staphylococcal cell, resulting in the production of highly immunogenic vaccine comprised of all staphylococcal proteins and cell-wall components. (immlab.com)
Vaccination2
- One of the main arguments that the medical profession use to get parents to consent to vaccination is the fear that the child might DIE of a vaccine-preventable disease, and they say that vaccination is to prevent deaths, save lives etc. (vaccineriskawareness.com)
- In the first phase, the vaccines as per the WHO list were administered at the vaccination center belonging to the UOSD of Hospital Hygiene to which patients, healthcare workers and students of the health care area belonging to the university polyclinic are addressed. (unime.it)
Antibody2
- A candidate vaccine from Merck, V710, appears safe and evoked an antibody response in healthy volunteers but is neither efficacious nor safe in surgical patients who become infected. (medscape.com)
- A gp120 subunit-based vaccine can thus elicit an antibody capable of tier 2-HIV neutralization. (bvsalud.org)
Interventions1
- These findings do not support the use of the V710 vaccine for patients undergoing surgical interventions," the researchers concur. (medscape.com)
ACIP1
- This report reviews ACIP recommendations for RSV vaccine in adults over 60. (medscape.com)
Pandemic1
- Only one question- naire survey of community pharmacy one occasion when an individuals genetic predisposition pain denotes a longitudinal study involves single doses from the early rehabilitation gupta v, lipsitz la (2002) persistent nonmalignant pain and increased risk of delirium: A systematic approach targeted at making peptide administered in the 2005 pandemic h1n1 vaccine, j allergy clin immunol 106(4):553, 1997. (stonecottagegardens.com)
Injections2
- But allegedly if the laws have applied, the vials of the vaccine with the gray cap and the NDC [National Drug Code] codes that were issued on December 22, 2021, are lethal injections. (naturalnews.com)
- Identification of the Negri bodies in the brain of an 8-year-old boy who died 8 days after a paralytic illness and 20 days after a dog bite, and who had received 9 injections of Semple's anti-rabies vaccine, provided evidence that he died of acute rabies encephalitis and not of post-vaccinal allergic encephalomyelitis. (vaccineriskawareness.com)
Potentially1
- The first vaccine to potentially prevent Staphylococcal-induced Toxic Shock Syndrome (TSS) has successfully completed a Phase 2 study. (noticiadesalud.com)
Placebo1
- The investigators randomly assigned 4015 patients to receive the vaccine within 14 to 60 days of cardiothoracic surgery and 4016 to receive a placebo. (medscape.com)
Recipients1
- Like in gambling, recipients of the vaccine will have no choice but to accept what happens to them. (naturalnews.com)
Researchers1
- Stratifying participants by those who became infected revealed a possible exacerbating association to the vaccine, although the researchers caution that this is not causal evidence. (medscape.com)
Increasingly1
- At the same time, the last 25 years have been marked by the increasing development, in the pharmaceutical field, of increasingly effective vaccines, such as those directed against pneumococci, Haemophilus influenzae type b (Hib), Rotavirus and, recently, ACWY meningococcus and B, as well as the most innovative flu vaccines. (unime.it)
Effective2
- Scientists have been looking for an effective vaccine for over a century, with at least 15 successful preclinical studies using animal models in the last 30 years. (scienceinter.com)
- Vaccines are the most effective way to reduce that health burden and antibiotic resistance," Liu said, citing successes with childhood immunizations and the more recent COVID-19 vaccines as examples. (scienceinter.com)
Clinical trial1
- Vance G. Fowler Jr, MD, MHS, from Duke University Medical Center, Durham, North Carolina, and colleagues conducted a multicenter, 4-year, primary modified intention-to-treat randomized phase 2b/3 clinical trial evaluating a single intramuscular injection of vaccine. (medscape.com)
Fever1
- Typhus also disappeared without any vaccine, as did Scarlet Fever. (vaccineriskawareness.com)
Cite1
- Cite this: S aureus Vaccine for Heart Surgery Appears Harmful - Medscape - Apr 02, 2013. (medscape.com)
Colonization1
- Previous studies with rodent models of nasal colonization have implicated capsule and teichoic acid as staphylococcal surface factors that promote colonization. (unipv.it)
Respiratory1
- Use of Respiratory Syncytial Virus Vaccines in Older Adults While RSV is usually associated with young children, it can also cause severe respiratory illness in older adults. (medscape.com)
Reactions1
- And so that would explain why we're having such rash differentiations between reactions to the vaccine . (naturalnews.com)
Potential1
- Liu hypothesized, along with first author Chih-Ming Tsai, PhD, a project scientist in his lab, and others, that while laboratory mice with no previous exposure to S. aureus respond well to potential vaccines because they are completely novel, human versions do not because S. aureus has evolved defenses to fend off the therapeutic attack. (scienceinter.com)
Allergy1
- Development of a poly (lactic-co-glycolic acid) particle vaccine to protect against house dust mite induced allergy. (southernbiotech.com)
Illness1
- No parent would accept a vaccine for an illness they thought their child would easily recover from. (vaccineriskawareness.com)
Development2
- The ever-increasing genomic and proteomic data has greatly facilitated the vaccine designing and development process. (biomedcentral.com)
- The EVX-B1 vaccine candidate is ready for non-clinical development, CMC, and subsequent clinical testing. (evaxion-biotech.com)
Candidate1
- Schistosoma mansoni tetraspanning orphan receptor (SmTOR): a new vaccine candidate against schistosomiasis. (southernbiotech.com)
Disease1
- If you notice, when the vaccine was introduced in the 1920's, the disease and death rates spiked on the graph, before reducing again, suggesting a relation to the vaccine. (vaccineriskawareness.com)
Phase1
- With highly encouraging data from the Phase 2 study building on a successful Phase 1, we believe the TSST-1 vaccine could represent a real breakthrough in protecting these groups, as well as medical workers in at-risk settings. (noticiadesalud.com)
Attempts1
- Attempts to develop a vaccine in the past have been futile. (scienceinter.com)
Target1
- EVX-B1 has been designed using Evaxion's proprietary AI technology for vaccine target discovery. (evaxion-biotech.com)
Medical1
- A successful preventative vaccine could also be used to protect medical staff. (noticiadesalud.com)
Previous1
- But it does give us a sub-set of data to compare to all other FDA-approved vaccines for the previous 30 years (360 months) prior to the roll out of the COVID-19 vaccines. (healthimpactnews.com)
Surface1
- The vaccine is based on the 0657nI iron surface determinant B. (medscape.com)